Welcome to our dedicated page for ILLUMINA SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
ILLUMINA, INC. Vice President and Chief Accounting Officer Scott D. Ericksen reported open-market sales of company common stock. He sold 1,500 shares on May 28, 2026 at $150.10 per share and 500 shares on May 29, 2026 at $160.00 per share. Following these transactions, he directly owns 14,446 shares of Illumina common stock.
Corvex Management LP reported sales of Common Stock of Illumina, Inc. The filing lists four open‑market transactions: 225,067 shares on 05/13/2026, 104,393 shares on 05/14/2026, 220,000 shares on 05/28/2026, and 50,540 shares on 05/29/2026. Each row includes the cash proceeds for that trade.
Illumina-related reporting person reported a sale of 1,500 shares of common stock on 05/28/2026 under a 10b5-1 plan, generating $225,150 in proceeds. The filing also lists 478 Restricted Stock Units and an Employee Stock Purchase Plan allocation of 500 shares.
ILLUMINA, INC. director Keith A. Meister filed an amended Form 4 to update his indirect holdings in the company’s common stock. The filing reports that entities associated with him hold 3,500,048 shares of Illumina common stock indirectly.
According to the disclosure, these shares are held for the accounts of certain private investment funds collectively referred to as the Corvex Funds, for which Corvex Management LP acts as investment adviser. The balance was adjusted to reflect transactions previously reported in a separate Form 4 filed on May 14, 2026, and this amendment itself does not report new purchases or sales.
Illumina reported a Form 144 notice indicating a proposed sale of 1,500 shares of Common Stock through Morgan Stanley Smith Barney LLC. The filing lists an aggregate amount of $225,255.00 and references 151,300,000 alongside a 05/28/2026 label. The securities identified include Restricted Stock Units (1,040) dated 11/05/2023 and Employee Stock Purchase Plan shares (460) dated 08/01/2014. The notice is a resale filing and reports the broker and methods for sale.
Frances Arnold reported proposed and recent sales of Illumina common stock under Rule 144. The filing lists 5,000 shares as securities to be sold, describing restricted stock vesting under a registered plan on 05/21/2026 with the issuer identified as Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also discloses prior sales of 3,000 shares and 1,000 shares on 05/22/2026, with gross proceeds reported as $435,076.08 and $145,072.06, respectively.
Illumina, Inc. reported the final voting results from its 2026 annual meeting of stockholders. Stockholders elected nine directors, ratified the appointment of Ernst & Young LLP as independent auditor for the fiscal year ending January 3, 2027, and approved on an advisory basis the compensation of the company’s named executive officers.
There were 151,906,915 votes underlying issued and outstanding shares of common stock as of the March 26, 2026 record date. At the meeting, 141,044,031 votes were present in person or by proxy, representing 92.85% of the voting power entitled to vote, which constituted a quorum.
KING DAVID P reported acquisition or exercise transactions in this Form 4 filing.
ILLUMINA, INC. director David P. King received an equity grant of 2,072 shares of common stock in the form of restricted stock units, valued at $144.83 per share. The award vests 100% on the earlier of one year from the grant date or immediately before the next annual stockholders’ meeting, assuming he continues to serve as a director.
SIEGEL SUSAN E reported acquisition or exercise transactions in this Form 4 filing.
ILLUMINA, INC. director Susan E. Siegel reported a grant of 2,072 shares of common stock as a restricted stock unit award at a reference price of $144.83 per share. After this grant, she holds 16,535 shares directly and 4,006 shares indirectly through the Reed-Siegel Revocable Trust. The RSUs vest 100% on the earlier of one year from grant or immediately before the next annual stockholder meeting, if she continues serving as a director.